TP53 Splice Mutations Have Tumour-Independent Effects on Genomic Stability and Prognosis: An In Silico Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262412080 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Apeksha Arun Bhandarkar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Otago, Dunedin 9016, New Zealand. Hauptthemen laut MEDLINE: Genomic Instability, Tumor Suppressor Protein p53, Neoplasms, Mutation. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Maurice Wilkins Centre, University of Otago.
Abstract (Originalsprache)
The tumour suppressor TP53 (tumor protein p53) is a master regulator of cell cycle, DNA repair, and apoptosis, and its mutation is a hallmark of cancer, with individual mutations exerting distinct effects on tumour biology. Despite accounting for ~7% of all TP53 variants, splice site mutations remain the least studied class, and their functional and clinical consequences are poorly understood. We analyzed 25,058 TP53 variants (18,562 somatic; 6496 germline) to characterize the frequency, molecular impact, transcriptional effects, genomic instability, and clinical outcomes of splice mutations. These alterations showed distinct distributions and substitution patterns between germline and somatic contexts and were frequently associated with copy number alterations, reduced TP53 mRNA, and variable protein expression. Transcriptomic profiling identified two transcriptional phenotypes: one with global suppression of canonical p53 target genes and another with mixed activation and repression independent of tumour type. Genomic instability was elevated in a subset of splice-mutant tumours, correlating with increased relapse risk, while other splice mutations showed lower instability but divergent clinical outcomes, including unexpectedly poor prognoses. Our findings fill a critical knowledge gap, defining the biological and clinical spectrum of TP53 splice site mutations and highlighting their potential as prognostic biomarkers and therapeutic targets in precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Otago, Dunedin 9016, New Zealand.
- Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland 1142, New Zealand.
- Medical Laboratory Science, University of Otago, Dunedin 9016, New Zealand.
ORCID-Profile: Debina Sarkar, Tania Slatter, Sunali Mehta
Förderung
- Health Research Council of New Zealand
- Maurice Wilkins Centre
- University of Otago
Zitieren
APA
Bhandarkar, A. A., Kelly-Foleni, N. E., Sarkar, D., Jeffs, A., Slatter, T., Braithwaite, A., & Mehta, S. (2025). TP53 Splice Mutations Have Tumour-Independent Effects on Genomic Stability and Prognosis: An In Silico Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262412080
Vancouver
Bhandarkar AA, Kelly-Foleni NE, Sarkar D, Jeffs A, Slatter T, Braithwaite A, et al. TP53 Splice Mutations Have Tumour-Independent Effects on Genomic Stability and Prognosis: An In Silico Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262412080
BibTeX
@article{Bhandarkar2025,
author = {Bhandarkar, Apeksha Arun and Kelly-Foleni, Noah Ethan and Sarkar, Debina and Jeffs, Aaron and Slatter, Tania and Braithwaite, Antony and Mehta, Sunali},
title = {TP53 Splice Mutations Have Tumour-Independent Effects on Genomic Stability and Prognosis: An In Silico Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262412080}
}
EUVIMED